Navigation Links
Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
Date:5/31/2008

new cases and over 45,000 deaths annually.

About VELCADE

VELCADE is being co-developed by Millennium Pharmaceuticals, The Takeda Oncology Company, and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Millennium is responsible for commercialization of VELCADE in the U.S. and Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. For a limited period of time, Millennium and Ortho Biotech Inc. are co-promoting VELCADE in the U.S. VELCADE is approved in 85 countries worldwide. More than 100,000 patients have been treated with VELCADE globally.

In the U.S., VELCADE is indicated for the treatment of patients with multiple myeloma who have received at least one prior therapy. VELCADE is also indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy. In the European Union and many other countries worldwide, VELCADE is approved for patients with multiple myeloma after first relapse.

Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart failure, and/or new onset of decreased left ventricular ejection fraction has been reported, including reports in patients with
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
3. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
4. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
5. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
6. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
7. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
10. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
11. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... VIEW, California , 20 de octubre de ... líder en el campo de la pulmonología intervencional, ... su Estudio RENEW, casi 3 meses antes de ... fundamental de exención de dispositivo de investigación (IDE) ... Medicamentos) para el sistema de espiral de reducción ...
(Date:10/20/2014)... SAN DIEGO , Oct. 20, 2014   BioNano ... the Irys system: the ability to collect human data at ... on a single chip.  This new capability was established and ... for the Irys TM System and will ... next two months. BioNano will be showcasing this advancement at ...
(Date:10/20/2014)...   Mary,s Medicinals today announced that its ... Sponsor of Operation Grow4Vets , a national, nonpartisan ... and services to assist them in living with injuries ... , An ever-increasing number of medical studies ... treatment for pain, Post-traumatic Stress Disorder (PTSD) and Traumatic ...
Breaking Medicine Technology:PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 2Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 3
... 2011 Reportlinker.com announces that a new market research report ... In Vitro Diagnostics Market http://www.reportlinker.com/p0470752/World-In-Vitro-Diagnostics-Market.html ... through 2014 The Freedonia Group projects world ... annually to nearly $68 billion in 2014. Based on the ...
... Reportlinker.com announces that a new market research report ... European Markets for Patient Monitoring Devices and Equipment ... In 2010, the European patient monitoring ... 2008 and 2009. This mature market is expected ...
Cached Medicine Technology:Reportlinker Adds World In Vitro Diagnostics Market 2Reportlinker Adds World In Vitro Diagnostics Market 3Reportlinker Adds World In Vitro Diagnostics Market 4Reportlinker Adds World In Vitro Diagnostics Market 5Reportlinker Adds World In Vitro Diagnostics Market 6Reportlinker Adds World In Vitro Diagnostics Market 7Reportlinker Adds World In Vitro Diagnostics Market 8Reportlinker Adds World In Vitro Diagnostics Market 9Reportlinker Adds European Markets for Patient Monitoring Devices and Equipment 2011(15 Countries) 2Reportlinker Adds European Markets for Patient Monitoring Devices and Equipment 2011(15 Countries) 3Reportlinker Adds European Markets for Patient Monitoring Devices and Equipment 2011(15 Countries) 4Reportlinker Adds European Markets for Patient Monitoring Devices and Equipment 2011(15 Countries) 5Reportlinker Adds European Markets for Patient Monitoring Devices and Equipment 2011(15 Countries) 6Reportlinker Adds European Markets for Patient Monitoring Devices and Equipment 2011(15 Countries) 7Reportlinker Adds European Markets for Patient Monitoring Devices and Equipment 2011(15 Countries) 8Reportlinker Adds European Markets for Patient Monitoring Devices and Equipment 2011(15 Countries) 9Reportlinker Adds European Markets for Patient Monitoring Devices and Equipment 2011(15 Countries) 10Reportlinker Adds European Markets for Patient Monitoring Devices and Equipment 2011(15 Countries) 11Reportlinker Adds European Markets for Patient Monitoring Devices and Equipment 2011(15 Countries) 12Reportlinker Adds European Markets for Patient Monitoring Devices and Equipment 2011(15 Countries) 13Reportlinker Adds European Markets for Patient Monitoring Devices and Equipment 2011(15 Countries) 14Reportlinker Adds European Markets for Patient Monitoring Devices and Equipment 2011(15 Countries) 15Reportlinker Adds European Markets for Patient Monitoring Devices and Equipment 2011(15 Countries) 16Reportlinker Adds European Markets for Patient Monitoring Devices and Equipment 2011(15 Countries) 17Reportlinker Adds European Markets for Patient Monitoring Devices and Equipment 2011(15 Countries) 18Reportlinker Adds European Markets for Patient Monitoring Devices and Equipment 2011(15 Countries) 19Reportlinker Adds European Markets for Patient Monitoring Devices and Equipment 2011(15 Countries) 20Reportlinker Adds European Markets for Patient Monitoring Devices and Equipment 2011(15 Countries) 21
(Date:10/20/2014)... (PRWEB) October 20, 2014 Based ... are the only imaging assays capable of determining ... single test.  With these three dimensions of high-resolution ... to detect the widest range of disease-causing genetic ... missed by other genomic tools, including today’s advanced ...
(Date:10/20/2014)... 2014 Unveiled at the Sept. 18 board ... conservatively estimates member hospital ROI on membership dues at 12.5. ... Center provides $12.50 in value to member hospitals. The calculation ... Member Dues)/Member Dues. , “This is the first time ... we think the methodology is really sound,” said Bill ...
(Date:10/20/2014)... Houston, Texas (PRWEB) October 20, 2014 ... invited to present the key elements of his innovative ... visiting professor to plastic surgery residents and faculty at ... (UTMB) , where he, too, was once a medical ... of the largest private cosmetic plastic surgery practices in ...
(Date:10/19/2014)... October 20, 2014 The leading ... ( http://www.top10bestseohosting.com/go/iPage/ ) and GreenGeeks are the best ... platforms for those who want to buy high ... time. , The IT manager of Top10BestSEOHosting.com says, ... most recommended suppliers for everyone. A lot of ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 This ... for Partial Seizure, complete with comparative analysis at ... of action (MoA), route of administration (RoA) and ... news and press releases. It also reviews key ... Seizure and special features on late-stage and discontinued ...
Breaking Medicine News(10 mins):Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4
... simple diagnostic modality can help predict the outcome of ... It can predict which patient would benefit from the ... valuable study can be found in the latest issue ... physicians identify factors that cause specific symptoms by demonstrating ...
... prescription drugs in the filtered and recycled wastewater at ... dangerous effects this water might have in the future. ... antibiotics, antipsychotics, birth-control hormones, Viagra and Valium have been ... the wastewater is because people flush them down their ...
... Boston, a surgery was conducted on a baby inside the womb. ... the womb. // She was discharged on Friday after the successful ... a heart defect called hypoplastic left heart syndrome (HLHS) inside the ... in the developing fetus on November 7, 2005. ,She ...
... services in a hospital at Brisbane a patient had to ... was attacked and was in serious condition, attention could not ... Caboolture Hospital, where emergency services are scarce due to shortage ... presently operational from 8am to 6pm every day. ...
... announced that it intends to fast track its inhaled insulin ... Food and Drug Administration // and the European Commission ... Sanofi-Aventis and Nektar Therapeutics. ,It is a relatively ... or syringes are needed. "Until today, patients with diabetes who ...
... successfully reached the Vinson Massif summit, one of Antarctica's ... and was successfully completed on January 19th after eight ... was a strong, healthy athlete who was later diagnosed ... of the disease he lost 80 pounds and his ...
Cached Medicine News:Health News:SPECT Can Help Predict Treatment Outcome In Patients With Low Back Pain 2Health News:Medications Detected In Recycled Water In Los Angeles 2Health News:Baby Underwent A Heart Surgery Inside The Womb 2Health News:Crohn's Patient Robert Hill’s greatest achievemen 2
Toothed grasping forcep....
Bateman pituitary forceps, round cup, 5 mm bite, fenestrated crocodile jaws, 150 mm effective....
Micro cup pituitary forceps, semi-malleable shafts....
Bayonet Kerrison Rongeur, ceramic ejector, 9.5 length 40 Fwd, 6.5 working length 165 mm....
Medicine Products: